Serve Pfizer Inc.: 37-State CT Corporation RA Architecture

As of 2026, Pfizer Inc. is a Delaware corporation maintaining active foreign-qualification filings in thirty-seven states, with C T Corporation System designated as the registered agent across the entire architecture, supporting service of process in any forum state through a single uniform registered-agent network rather than through corporate-headquarters address.

Why Service of Process on Pfizer Inc. Requires Operational Authority, Not Improvisation

Service of process on Pfizer Inc. is determined by where the matter is filed, not by where Pfizer’s principal executive offices are located in any given calendar year. In nearly every state where Pfizer maintains an active corporate filing, the registered agent of record is C T Corporation System at that state’s CT Corporation office address. Pfizer is incorporated in Delaware (Delaware filing dated June 2, 1942), and the architecture has remained operationally stable across more than eight decades and roughly $128 billion of pharmaceutical M&A activity layered on top of the parent corporate structure. The architecture is the load-bearing question for service: the entity to be served is Pfizer Inc.; the address is the state-specific C T Corporation System registered agent for the forum state of the matter. Operating-site addresses, manufacturing-plant addresses, R&D-campus addresses, and Pfizer-affiliated commercial premises are not authorized service venues for the corporate entity, regardless of how prominent those addresses appear in Pfizer public communications, SEC filings, or trade-press coverage of Pfizer operations.

For matters filed in New York federal districts (SDNY, EDNY, NDNY, WDNY) or in New York state court, service on Pfizer Inc. routes to C T Corporation System at 28 Liberty Street, New York, NY 10005, the registered-agent designation under Pfizer’s New York foreign-qualification filing dated June 25, 1951. Counsel managing high-volume New York commercial-litigation matters or pharmaceutical-product-liability matters can reach Undisputed Legal’s New York metro coordination desk at (212) 203-8001 for pre-dispatch verification of the current Pfizer registered-agent designation, multi-state coordination when matters span more than one Pfizer-qualified state, and same-day or next-day dispatch coordination across the Pfizer thirty-seven-state foreign-qualification architecture.

Undisputed Legal coordinates Pfizer Inc. service across the Delaware state of incorporation and the thirty-seven verified active foreign-qualification states, with state-specific registered-agent verification adapted to each forum state’s substantive procedural framework and to the specific Pfizer subsidiary that may be the proper-party defendant on a matter rooted in product liability, patent litigation, employment dispute, or commercial action. To order service on Pfizer Inc. in any forum state — federal or state, in Delaware as the state of incorporation or in any of the thirty-seven active foreign-qualification jurisdictions — call (800) 774-6922 or use the link below.

Order Pfizer Inc. Service Now

What Makes Service of Process on Pfizer Inc. Operationally Distinctive

Pfizer Inc. presents three structural facts that determine how service of process actually routes on a litigation matter, and each fact has direct operational consequences for counsel and process-service vendors. First, Pfizer’s corporate history spans more than eighty years and includes substantial M&A activity that has stacked subsidiary entities into the parent corporate tree across acquisitions of Pharmacia & Upjohn (2003), Wyeth (2009), Hospira (2015), and most recently Seagen (December 2023). Each acquisition brought separately-organized legal entities into the Pfizer family that hold specific New Drug Applications (NDAs), patents, and manufacturing approvals. Second, the thirty-seven-state foreign-qualification architecture means that service routing is uniform across the network — C T Corporation System is the registered agent in nearly every state — but the architecture is not absolute, with two states using CT Corporation’s state-specific subsidiary brands rather than the C T Corporation System name itself. Third, Pfizer relocated its global headquarters from 235 East 42nd Street to The Spiral at 66 Hudson Boulevard East in 2022, and stale-record risk is real for litigation matters predating the relocation.

Subsidiary Disambiguation Across $128 Billion of M&A Activity

The Pfizer family includes five subsidiaries that routinely appear as captioned defendants on litigation matters: Wyeth LLC, Hospira, Inc., Greenstone LLC, Seagen Inc., and Pharmacia & Upjohn Company LLC. Each subsidiary holds specific products, NDAs, patents, or manufacturing approvals, and the captioned-party determination affects which entity is the proper defendant, which registered agent receives service, and how the docket reads. A complaint captioned against “Pfizer Inc.” for a Wyeth-legacy pediatric-vaccine matter is not the same operational filing as one captioned against “Wyeth LLC” for the same underlying product. The Pfizer parent and the Wyeth subsidiary are both Delaware entities served through C T Corporation System, but the registered-agent letter, the docket caption, and any subsequent litigation activity flow through different legal entities. Counsel must determine which subsidiary holds the product NDA or patent at issue before captioning a complaint, and pre-dispatch verification confirms the registered-agent designation has not changed during the discovery period or since the most recent state filing.

Thirty-Seven-State Architecture with State-Specific Subsidiary Brand Variations

The C T Corporation System network covers the great majority of Pfizer’s foreign-qualification states under the C T Corporation System name. Two states, however, use CT Corporation’s state-specific subsidiary brands: Maryland filings list “The Corporation Trust, Incorporated” as the registered agent, and Michigan filings list “The Corporation Company.” These are not separate legal entities — they are CT Corporation’s state-specific filing names — but service-of-process documents must address the registered agent under the precise name on the state filing. A document addressed to “C T Corporation System” in Maryland, where the state filing names “The Corporation Trust, Incorporated,” may be challenged as technically defective service. The state filing controls the address-of-record name; counsel must verify the registered-agent name matches the state filing exactly before dispatch.

The 2022 Headquarters Relocation and the Stale-Record Risk

Pfizer relocated its global headquarters from 235 East 42nd Street, New York, NY 10017 to The Spiral at 66 Hudson Boulevard East, New York, NY 10001-2189 in 2022. SEC filings made before mid-2022 reference the legacy 42nd Street address; SEC filings from late 2022 forward reference the current 66 Hudson Boulevard East address. Stale-record risk is real for older complaints, demand letters, or settlement-negotiation correspondence that was prepared from outdated templates and continues to reference the 42nd Street address. Service of process on the corporate entity itself routes through C T Corporation System in the forum state, not through either Pfizer headquarters address — but operational correspondence that depends on a current Pfizer mailing address must reflect 66 Hudson Boulevard East as of any document prepared after the 2022 relocation. The legacy address remains valid only in historical context (e.g., describing the Pfizer-prior-to-2022 operational footprint or referencing pre-2022 SEC filings).

C T Corporation System and the 37-State Pharmaceutical RA Architecture: Why Service on Pfizer Routes Through One Network

The thirty-seven-state foreign-qualification architecture is the operational heart of how service of process actually works on Pfizer Inc. matters. This section maps the architecture itself, describes why CT Corporation rather than CSC anchors the network, identifies the state-specific subsidiary brand variations, and explains the Tier 2 verification layer that Undisputed Legal applies to every Pfizer matter before dispatch.

The Architecture Itself: 37 Active Foreign-Qualification States Plus Delaware State of Organization

Pfizer Inc. maintains active foreign-qualification filings in thirty-seven states as of the 2026 Accurint pull dated 05/09/2026, with the earliest active filing dating to June 25, 1951 (California, Connecticut, Illinois, and New York, all on the same date) and the most recent active filing dating to December 17, 2002 (Kentucky). The thirty-seven active foreign-qualification states span every major regional cluster in the United States: the Northeast (Connecticut, Maine, Massachusetts, New Hampshire, New York), the Mid-Atlantic (Maryland, Virginia, West Virginia), the Southeast (Florida, Georgia, Kentucky, Mississippi, North Carolina, Tennessee), the Midwest (Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota), the Mountain West (Arizona, Colorado, Idaho, Montana, Nevada, Utah, Wyoming), and the Pacific (Alaska, California, Hawaii, Oregon, Washington). The Delaware state of organization is the legal home of the entity itself, where service routes through the Delaware Secretary of State or through the Delaware-registered agent for matters filed in Delaware Court of Chancery, the Delaware Superior Court, or the Delaware federal district. Three additional jurisdictions (Alabama, the District of Columbia, and Vermont) carry N/A status filings reflecting legacy filings that are not currently in active operational status; service in those forums requires pre-dispatch confirmation through the state Secretary of State that the legacy filing remains a valid service venue or that an alternative service venue applies.

Why CT Corporation, Not CSC: The Pharmaceutical Industry’s Registered-Agent Backbone

Pfizer’s selection of C T Corporation System as the unified registered agent across nearly every active foreign-qualification state is consistent with broader pharmaceutical-industry practice. CT Corporation has historically served as the dominant registered-agent network for pharmaceutical and life-sciences entities, while Corporation Service Company (CSC) tends to anchor aerospace, defense, and certain heavy-industrial corporate networks. The two networks are operationally similar — each provides a uniform single-network registered-agent designation across thirty or more states — but the industry-historical separation runs deep enough that counsel familiar with one network’s filing patterns may not be familiar with the other’s. Pfizer’s relationship with CT Corporation predates CT Corporation’s various corporate ownership transitions (CT Corporation has been owned by Wolters Kluwer since 1995); the Pfizer-CT relationship is decades-old and stable across multiple parent-company changes on the CT side. Counsel preparing a Pfizer matter does not need to navigate which state-specific registered agent applies on a state-by-state basis — the answer is C T Corporation System in nearly every active state, with two specific state-subsidiary-brand variations and three N/A-status legacy filings to verify pre-dispatch.

The State-Specific Subsidiary Brand Variations

Two states require careful attention to the precise registered-agent name on the state filing. Maryland filings name “The Corporation Trust, Incorporated” at 2405 York Road, Suite 201, Lutherville Timonium, MD 21093-2252. Michigan filings name “The Corporation Company” at 40600 Ann Arbor Road East, Suite 201, Plymouth, MI 48170-4675. These are CT Corporation’s state-specific subsidiary brands — the same operational entity, the same parent network — but the state filing names a specific filing entity whose name controls the address-of-record on the registered-agent designation. Service-of-process documents should address the registered agent under the precise name listed on the state filing. A document addressed to “C T Corporation System” in Maryland or Michigan, where the state filing names a different filing entity, may be challenged as technically defective service. The conservative practice is to verify the registered-agent name through the state Secretary of State’s online business registry within the seventy-two-hour window before dispatch, confirming that (a) the registered-agent designation has not changed since the most recent annual-report filing, (b) the filing-entity name on the registered-agent line matches the document caption, and (c) the registered-agent address has not been updated to a new CT Corporation office location.

Operational Interaction with the Tier 2 Verification Layer

Tier 1 routing — the static state-by-state matrix of registered-agent designations — is necessary but not sufficient for service of process on Pfizer Inc. Tier 2 verification is the pre-dispatch step that confirms the static matrix matches current operational reality. On every Pfizer matter that Undisputed Legal coordinates, Tier 2 verification confirms four specific items before any process server is dispatched: first, that the registered-agent designation has not changed since the most recent annual-report filing in the forum state; second, that the registered-agent address has not been updated to a new CT Corporation office location (CT Corporation has restructured several state offices over the past five years, and address updates appear in the state Secretary of State filings before they propagate to commercial databases); third, that the entity status remains ACTIVE rather than transitioning to INACTIVE, SUSPENDED, or DISSOLVED; and fourth, that any name variations across the historical filings (Pfizer’s 1942 anchor filing in Alabama uses “PFIZER INC.” while later filings use slight format variations) are reconciled against the current docket caption. Pfizer’s registered-agent network is stable, but state-level address changes happen quarterly across thirty-seven states; static routing tables drift over twelve to twenty-four months without active maintenance. Tier 2 verification eliminates the drift risk and produces a contemporaneous record of the registered-agent designation as of the dispatch date, which is the controlling fact for any subsequent challenge to the validity of service.

CT Corporation has been a wholly-owned subsidiary of Wolters Kluwer N.V. since 1995. The Dutch information-services parent has maintained CT Corporation’s network footprint, expanded its compliance-services portfolio, and stabilized the registered-agent infrastructure across decades. The ownership stability matters operationally because the C T Corporation System filing-entity name has remained consistent across nearly every Pfizer state filing from 1942 forward, even through CT Corporation’s parent-company transitions. Counsel can reasonably treat the C T Corporation System designation as the operational anchor for Pfizer service of process across the foreign-qualification network without concern about parent-company-driven RA designation changes.

CT Corporation maintains state-specific filing offices that move locations approximately quarterly across the network as office leases turn over and as state filings update. The Tier 2 pre-dispatch verification protocol catches these address changes before any process server is dispatched, eliminating the risk that a static routing matrix produces a wrong-address service attempt. The 72-hour pre-dispatch window is engineered specifically to catch within-quarter address moves that the most recent annual-report filing would not yet reflect. Across Pfizer’s 37-state foreign-qualification network, an estimated 8-12 state-specific RA addresses change in any given calendar quarter — Tier 2 verification produces a contemporaneous record of the dispatched-to address as of the dispatch date for each state.

The two dominant nationwide registered-agent networks — C T Corporation System (Wolters Kluwer) and Corporation Service Company (CSC) — each maintain comparable 30+ state coverage but exhibit industry-segmentation patterns that influence how counsel approaches RA service across different defendant types. Pharmaceutical companies (Pfizer, Merck, Eli Lilly, Abbott Laboratories) are predominantly served via CT Corporation System. Aerospace and defense entities (The Boeing Company, Lockheed Martin, Raytheon Technologies) are predominantly served via CSC’s national network — an editorial centerpiece previously documented in the Boeing service-of-process page. Banking and financial-services entities split between the two networks depending on entity-specific historical RA designations. The industry-historical pattern means that counsel approaching a Pfizer matter for the first time can rely on CT Corporation System as the routing baseline; counsel approaching defense-sector entities should expect CSC routing instead. Both networks provide functionally equivalent operational capacity for service of process; the distinction is industry-historical rather than operational.

The Pfizer Subsidiary Tree: Five Caption-Discipline Targets That Determine Where Service Actually Routes

Pfizer Inc. is the parent corporation, but pharmaceutical product liability, patent litigation, employment matters, and commercial actions frequently turn on the proper-party question of which Pfizer subsidiary actually holds the relevant NDA, patent, or manufacturing approval. The SEC 10-K Exhibit 21 filed February 26, 2026 (covering the fiscal year ending December 31, 2025) lists the full subsidiary roster; five subsidiaries appear with sufficient frequency in commercial litigation to warrant individual caption-discipline review.

Wyeth LLC (Delaware): The 2009 American Home Products Successor

Wyeth LLC is a Delaware limited liability company, wholly owned by Pfizer Inc. since the 2009 acquisition. Pfizer acquired Wyeth on October 15, 2009 for approximately sixty-eight billion dollars, in what was at the time the largest pharmaceutical acquisition in industry history. Wyeth LLC holds the legacy Wyeth-branded product NDAs that survived the acquisition and the corporate restructuring that followed: the Effexor antidepressant franchise, the Premarin hormone-replacement franchise, the pediatric-vaccine portfolio (Prevnar and certain other Wyeth-legacy vaccines), and historically the Centrum nutritionals portfolio prior to the divestiture of Centrum to other corporate ownership. The caption-discipline risk on Wyeth LLC is substantial because Wyeth’s pre-2009 corporate identity was American Home Products Corporation, and Wyeth-legacy product liability complaints filed during the long-tail discovery-rule periods that apply to certain pharmaceutical product liability claims may caption “Wyeth Inc.” or “American Home Products Corporation” rather than the current Wyeth LLC. Service of process on Wyeth LLC routes through Pfizer Inc.’s C T Corporation System network as Wyeth LLC’s registered agent in each state, but the docket caption controls the proper-party determination, and a stale caption that names a predecessor corporate identity may be challenged as misidentifying the proper defendant.

Effexor (venlafaxine) was the antidepressant at the center of multidistrict-litigation product-liability claims that originated under Wyeth before the 2009 Pfizer acquisition; complaints filed post-2009 must caption Wyeth LLC as the NDA-holder regardless of whether the alleged injury or product use occurred under the pre-acquisition Wyeth corporate identity. Premarin (conjugated estrogens) is the hormone-replacement therapy at the center of the long-running Prempro MDL coordinated in the Eastern District of Arkansas, with caption discipline turning on the distinction between the original branded Wyeth-Ayerst Premarin/Prempro NDAs (now held by Wyeth LLC) and any authorized-generic versions distributed through Greenstone LLC. Counsel handling Wyeth-product matters should verify the specific NDA-holder of record at the matter intake stage, including for Effexor extended-release formulations, Premarin-derivative hormone therapies, and any pediatric vaccine in the Prevnar family of Wyeth-legacy approvals that survived the post-acquisition portfolio rationalization.

Hospira, Inc. (Delaware): The 2015 Sterile Injectables and Biosimilars Acquisition

Hospira, Inc. is a Delaware corporation, wholly owned by Pfizer Inc. since the 2015 acquisition. Pfizer acquired Hospira on September 3, 2015 for approximately seventeen billion dollars. Hospira holds the sterile-injectables product portfolio (vials, prefilled syringes, single-dose and multi-dose injectables across antibiotics, oncology, and critical-care therapeutic categories), the contract-manufacturing portfolio for hospital sterile compounding, and a substantial biosimilars development pipeline. The caption-discipline risk on Hospira, Inc. operates differently than on Wyeth LLC: sterile-injectables product liability matters frequently caption Hospira, Inc. as a separate defendant alongside or instead of Pfizer Inc. because the Hospira-branded product packaging, the FDA-registered manufacturing facility, and the NDA-holder designation all name Hospira, Inc. rather than the Pfizer parent. Biosimilars patent litigation similarly captions Hospira, Inc. on biosimilar Abbreviated New Drug Applications (ANDAs) where Hospira is the FDA-designated applicant. Service of process on Hospira, Inc. routes through C T Corporation System but the proper-party caption requires careful identification of which entity actually holds the NDA, the manufacturing approval, or the biosimilar ANDA on the specific product at issue.

Sterile injectables (vials, prefilled syringes, infusion-pump cartridges) and biosimilars (Inflectra/infliximab-dyyb, Retacrit/epoetin alfa-epbx, Nyvepria/pegfilgrastim-apgf) are the two product categories that drive Hospira-specific product-liability and patent-litigation captioning. Sterile-injectables product-liability complaints typically caption Hospira, Inc. as the manufacturer of record because the FDA-registered facility producing the dosage form is registered under Hospira’s establishment registration rather than under Pfizer’s corporate establishment registration. Biosimilars patent litigation under the Biologics Price Competition and Innovation Act (BPCIA) involves Hospira, Inc. as the biosimilar applicant, with the reference-product sponsor (typically a non-Pfizer entity) on the opposing side of the BPCIA “patent dance” exchange. Patent-infringement and Hatch-Waxman litigation involving Hospira-developed sterile injectables typically captions Hospira, Inc. as the principal defendant alongside Pfizer Inc. as the parent corporate entity for liability-aggregation purposes.

Greenstone LLC (Delaware): The Authorized Generics Distribution Subsidiary

Greenstone LLC is a Delaware limited liability company, wholly owned by Pfizer Inc. and operated as the authorized-generics distribution subsidiary. Greenstone distributes Pfizer-branded authorized-generic equivalents of off-patent products under generic-equivalent NDAs, allowing Pfizer to maintain commercial presence in therapeutic categories where the original branded product has lost patent exclusivity. The caption-discipline risk on Greenstone LLC is specific to authorized-generic product liability: a complaint that captions “Pfizer Inc.” for an authorized-generic version of an off-patent product may misidentify the proper defendant, since the actual NDA-holder for the authorized-generic product is Greenstone LLC. The product-liability theory matters: a complaint alleging defects in the authorized-generic version of a former Pfizer-branded product should caption Greenstone LLC as the NDA-holder; a complaint alleging defects in the original branded version of the same product should caption Pfizer Inc. (or, where applicable, Wyeth LLC or Pharmacia & Upjohn Company LLC depending on the predecessor history). Mis-captioning shifts service of process to the wrong registered-agent designation and may produce service-of-process challenges that delay the merits of the matter.

Greenstone is Pfizer’s authorized-generics distribution subsidiary, organized as a Delaware limited liability company and operationally distinct from any third-party generic-drug manufacturer that may also produce a competing generic version of a former Pfizer-branded product. Authorized generics are produced under the same NDA approval as the branded counterpart but distributed under generic labeling and pricing; the distinction between an authorized-generic and a third-party generic matters because the NDA-holder for the authorized-generic version is the Pfizer-affiliated Greenstone LLC, not the original branded NDA-holder (Pfizer Inc., Wyeth LLC, or Pharmacia & Upjohn Company LLC depending on the predecessor history) and not any third-party generic manufacturer. Authorized-generic product-liability complaints captioning the wrong entity (e.g., naming Pfizer Inc. for an authorized-generic Effexor product when Greenstone LLC is the actual NDA-holder of record for the authorized-generic version, or naming a third-party generic manufacturer when Greenstone LLC produced the specific tablet at issue) face threshold proper-party challenges that delay substantive discovery and may produce dismissal-without-prejudice rulings before the merits are reached.

Seagen Inc. (Delaware): The 2023 Antibody-Drug Conjugate Oncology Acquisition

Seagen Inc. is a Delaware corporation, wholly owned by Pfizer Inc. since the December 14, 2023 acquisition. Pfizer acquired Seagen for approximately forty-three billion dollars, the largest Pfizer acquisition since the 2009 Wyeth transaction. Seagen holds the antibody-drug conjugate (ADC) oncology portfolio: Adcetris (brentuximab vedotin) for Hodgkin lymphoma and certain T-cell lymphomas, Padcev (enfortumab vedotin) for advanced urothelial cancer, Tukysa (tucatinib) for HER2-positive breast cancer and colorectal cancer, and Tivdak (tisotumab vedotin) for recurrent or metastatic cervical cancer. The caption-discipline risk on Seagen Inc. is structural and recency-driven: counsel handling oncology product liability or patent matters may not yet have updated CRM systems, document templates, or caption-defaults to reflect the current Pfizer-Seagen relationship that has only existed since December 2023. ADC oncology product liability complaints and oncology patent litigation must caption Seagen Inc. as the legal entity holding the ADC NDAs and the underlying ADC patent estate, even though the Pfizer parent now provides the broader corporate umbrella. Service of process on Seagen Inc. routes through C T Corporation System in each state where Seagen maintains foreign qualification, with the registered-agent designation under the Seagen-specific state filings rather than the parent Pfizer filings.

The ADC mechanism-of-action — a monoclonal antibody covalently bound to a cytotoxic payload through a chemical linker — creates distinct product-liability theory categories that differ materially from traditional small-molecule drug litigation. Manufacturing-defect theories on ADCs commonly turn on linker-chemistry stability, payload-release kinetics, and antibody-conjugation ratios; off-target cytotoxicity theories address the conjugate’s specificity profile rather than a small-molecule’s metabolic profile. Counsel preparing ADC-specific product-liability complaints must align the alleged defect with the conjugate-structure component at issue, which affects expert designations and discovery scope. The patent-estate dimension runs parallel: Seagen Inc. holds the foundational ADC platform-technology patents alongside the product-specific composition-of-matter and method-of-treatment patents on each approved ADC, and patent litigation divides between platform-level challenges and product-level challenges with materially different scope and expert-witness implications. ADCs as a class currently have no FDA-approved biosimilars because the conjugate-structure complexity renders BPCIA biosimilar approval pathways operationally difficult, which shapes any future biosimilar-challenger captioning.

Pharmacia & Upjohn Company LLC (Delaware): The 2003 Legacy with Long-Tail Tort Exposure

Pharmacia & Upjohn Company LLC is a Delaware limited liability company, wholly owned by Pfizer Inc. since the 2003 acquisition of Pharmacia Corporation. The acquisition closed on April 16, 2003, valuing Pharmacia at approximately sixty billion dollars. Pharmacia & Upjohn Company LLC holds the legacy Pharmacia-branded product NDAs and the ongoing tort exposure for pre-2003 Pharmacia products. The caption-discipline risk on Pharmacia & Upjohn Company LLC is the long-tail one: pharmaceutical product liability statutes of limitations are often long-running with discovery-rule provisions that allow filing decades after the original injury or product use, and pre-2003 Pharmacia product liability matters (Bextra and the broader COX-2 litigation cluster, Detrol, certain hormonal therapies) continue to surface in litigation more than two decades after the underlying acquisition. A complaint alleging defects in a pre-2003 Pharmacia-branded product should caption Pharmacia & Upjohn Company LLC as the NDA-successor entity, with Pfizer Inc. potentially named as the parent-company successor depending on the theory of liability and the controlling state’s successor-liability framework. Service of process routes through C T Corporation System in each state where Pharmacia & Upjohn Company LLC maintains foreign qualification.

The Bextra product-liability cluster was coordinated as In re Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL 1699, in the United States District Court for the Northern District of California, with caption discipline turning on whether the operative complaint correctly identifies Pharmacia & Upjohn Company LLC as the NDA-successor entity for any post-MDL individual matter or coordinated state-court parallel action. State-by-state statute-of-limitations discovery-rule mechanics produce materially different filing windows across jurisdictions: New York’s three-year SOL operates with a discovery-rule extension under CPLR § 214-c that runs from injury discovery rather than from product use; California’s two-year SOL operates with a delayed-discovery rule under Code of Civil Procedure § 340.8; and Texas’s two-year SOL operates under the legal-injury rule modified by the Texas Pharmaceutical Liability Act. Successor-liability frameworks vary across jurisdictions in parallel: the mere-continuation doctrine, the de facto merger doctrine, and the product-line continuity test produce different outcomes on whether Pfizer Inc. is liable as parent-corporate-successor for pre-2003 Pharmacia-branded products, and counsel of record retains responsibility for the substantive successor-liability analysis under the controlling state’s framework.

Smaller subsidiaries that appear less frequently in litigation but remain part of the Pfizer subsidiary tree, all Delaware entities unless otherwise noted, include: 356 Royalty Inc., Agouron Pharmaceuticals LLC (California), AH Robins LLC, Alpharma Pharmaceuticals LLC, Alpharma Specialty Pharma LLC, Amplyx Pharmaceuticals Inc., Anacor Pharmaceuticals LLC, Arena Pharmaceuticals Inc., Arixa Pharmaceuticals Inc., Array BioPharma Inc., Bamboo Therapeutics Inc., Biohaven Pharmaceutical Holding Company Limited (British Virgin Islands), and Blue Whale Re Ltd. (Vermont, the Pfizer reinsurance captive). Counsel handling matters that may implicate one of these smaller entities should consult the SEC 10-K Exhibit 21 filed February 26, 2026 for the contemporaneous subsidiary roster as of the most recent fiscal year, and Undisputed Legal can verify the registered-agent designation for any specific subsidiary as part of the Tier 2 pre-dispatch verification protocol.

On Pfizer matters, the proper-party caption determines whether service routes to Pfizer Inc. or to one of five Delaware subsidiaries.

Where to Serve Pfizer Inc.: The 37-State Foreign-Qualification Routing Matrix

The thirty-seven-state foreign-qualification routing matrix below represents the Tier 1 static routing as verified through the Accurint Comprehensive Business Report dated May 9, 2026 and reconciled against the SEC 10-K filing for fiscal year 2025. Tier 1 routing is the static state-by-state matrix of registered-agent designations and addresses; Tier 2 routing is the pre-dispatch verification protocol that Undisputed Legal applies to every Pfizer matter before any process server is dispatched. Counsel reviewing this matrix should treat it as the operational baseline rather than the dispatch authority — the dispatch authority is the contemporaneous Tier 2 verification record produced within the seventy-two-hour window before service.

State	Registered Agent	RA Address	Filing #	Filing Date
DE (state of organization)	Delaware Secretary of State (or DE-registered agent for the entity)	(Delaware Court of Chancery / Superior Court / D. Del.)	(incorporation 06/02/1942)	06/02/1942
NY	C T Corporation System	28 Liberty St, New York, NY 10005	(see Accurint pull)	06/25/1951
CA	C T Corporation System	(Sacramento, CA office)	(see Accurint pull)	06/25/1951
CT	C T Corporation System	(Hartford, CT office)	(see Accurint pull)	06/25/1951
IL	C T Corporation System	(Chicago, IL office)	(see Accurint pull)	06/25/1951
OH	C T Corporation System	(Columbus, OH office)	(see Accurint pull)	12/23/1954
NC	C T Corporation System	(Raleigh, NC office)	(see Accurint pull)	01/02/1958
GA	C T Corporation System	(Atlanta, GA office)	(see Accurint pull)	09/02/1952
MS	C T Corporation System	(Jackson, MS office)	(see Accurint pull)	06/24/1961
MA	C T Corporation System	(Boston, MA office)	(see Accurint pull)	10/18/1961
MO	C T Corporation System	(Jefferson City, MO office)	(see Accurint pull)	11/17/1961
CO	C T Corporation System	(Denver, CO office)	(see Accurint pull)	07/01/1963
NV	C T Corporation System	(Carson City, NV office)	(see Accurint pull)	03/22/1965
NE	C T Corporation System	(Lincoln, NE office)	(see Accurint pull)	01/23/1967
OR	C T Corporation System	(Salem, OR office)	(see Accurint pull)	05/04/1970
MT	C T Corporation System	(Helena, MT office)	(see Accurint pull)	12/06/1982
ND	C T Corporation System	(Bismarck, ND office)	(see Accurint pull)	10/16/1987
KS	C T Corporation System	(Topeka, KS office)	(see Accurint pull)	06/08/1993
TN	C T Corporation System	(Nashville, TN office)	(see Accurint pull)	02/01/1994
FL	C T Corporation System	(Tallahassee, FL office)	(see Accurint pull)	07/01/1996
VA	C T Corporation System	(Richmond, VA office)	(see Accurint pull)	07/09/1996
IA	C T Corporation System	(Des Moines, IA office)	(see Accurint pull)	09/02/1998
ID	C T Corporation System	(Boise, ID office)	(see Accurint pull)	02/22/2000
MN	C T Corporation System	(Minneapolis, MN office)	(see Accurint pull)	02/22/2000
UT	C T Corporation System	(Salt Lake City, UT office)	(see Accurint pull)	02/22/2000
MI	The Corporation Company	40600 Ann Arbor Rd E Ste 201, Plymouth, MI 48170-4675	801016099	02/29/2000
AZ	C T Corporation System	3800 N Central Ave Ste 460, Phoenix, AZ 85012-1995	F09417929	03/03/2000
WV	C T Corporation System	5098 Washington St W Ste 407, Charleston, WV 25313-1561	190674	03/03/2000
HI	C T Corporation System	900 Fort Street Mall Ste 1680, Honolulu, HI 96813-3716	20970 F1	03/06/2000
MD	The Corporation Trust, Incorporated	2405 York Rd Ste 201, Lutherville Timonium, MD 21093-2252	F05696364	03/06/2000
WY	C T Corporation System	2232 Dell Range Blvd Ste 200, Cheyenne, WY 82009-4942	2000-000402686	03/20/2000
SD	C T Corporation System	319 Coteau St, Pierre, SD 57501-3187	FB023690	03/22/2000
AK	C T Corporation System	8585 Old Dairy Rd Ste 208, Juneau, AK 99801-8094	69298F	03/28/2000
NH	C T Corporation System	2 1/2 Beacon St, Concord, NH 03301-4447	338833	04/05/2000
WA	C T Corporation System	711 Capitol Way S Ste 204, Olympia, WA 98501-1267	409006260	07/16/2002
KY	C T Corporation System	306 W Main St Ste 512, Frankfort, KY 40601-1840	0550167	12/17/2002
ME	C T Corporation System	(Augusta, ME office)	(see Accurint pull)	(legacy)
IN	C T Corporation System	(Indianapolis, IN office)	(see Accurint pull)	(legacy)
VT (N/A status)	C T Corporation System	(Burlington, VT office, legacy)	(legacy)	02/22/2000
DC (N/A status)	C T Corporation System	(Washington DC office, legacy)	(legacy)	09/03/1997
AL (N/A status)	C T Corporation System	(Montgomery, AL office, 1942 anchor filing)	(legacy)	06/02/1942

The matrix above represents the Tier 1 static routing as of the Accurint pull dated May 9, 2026. Tier 2 pre-dispatch verification confirms (a) the registered-agent designation has not changed since the most recent annual-report filing, (b) the registered-agent address has not been updated to a new CT Corporation office location, (c) the entity status remains ACTIVE on the state Secretary of State’s records, and (d) the filing-entity name on the registered-agent line matches the document caption verbatim. Counsel managing matters that span multiple states in the Pfizer foreign-qualification network can rely on Undisputed Legal to coordinate Tier 2 verification across all forum states simultaneously, producing a contemporaneous record of the registered-agent designation as of the dispatch date for each state.

Order Pfizer Inc. Service in Any Forum State

Operational Considerations Beyond the Routing Matrix

The routing matrix captures the static state-by-state architecture but does not capture several operational realities that affect how service of process actually executes on Pfizer matters in the field. Counsel preparing a Pfizer matter should account for the following operational considerations alongside the routing matrix.

First, the 2022 headquarters relocation timing affects the validity of any document prepared from a pre-2022 template that references the legacy 235 East 42nd Street address. Documents prepared after mid-2022 should reference 66 Hudson Boulevard East, New York, NY 10001-2189 as Pfizer’s current principal executive offices. The legacy address is acceptable in historical context (e.g., describing pre-2022 Pfizer operations or referencing pre-2022 SEC filings) but should not appear as the contemporary mailing address on a current matter.

Second, the state-specific subsidiary brand naming variations in Maryland and Michigan require document-level attention. A registered-agent letter or service-of-process cover sheet that addresses “C T Corporation System” in Maryland, where the state filing names “The Corporation Trust, Incorporated,” should be revised to address the registered agent under the precise filing-entity name. This is a clerical-precision item, not a substantive defect, but the conservative practice is to align the document caption with the state filing exactly.

Third, the service-versus-notice distinction matters on pharmaceutical product liability matters. Service of process — the formal delivery of a summons and complaint that initiates the lawsuit — routes through C T Corporation System in the forum state. Notice of pending litigation, settlement-negotiation correspondence, demand letters, and discovery requests directed to the corporate entity itself rather than to outside counsel of record may have different routing depending on the matter posture: in some matters, Pfizer’s in-house legal department at 66 Hudson Boulevard East accepts notice of pending litigation directly; in others, all litigation communication routes through outside counsel. Counsel should clarify the notice-routing question with Pfizer’s outside counsel of record at the matter intake stage rather than assuming notice-routing follows service-of-process routing.

Fourth, service hours, business-day windows, and same-day service feasibility from the Undisputed Legal New York metro coordination network produce different operational windows depending on the dispatch location. The New York metropolitan coordination desk supports same-day and next-business-day dispatch for service in the five New York City boroughs (Manhattan, Brooklyn, Queens, Bronx, Staten Island), in Nassau and Suffolk Counties on Long Island, and in Westchester and Rockland Counties to the immediate north. The Brooklyn metro service team, the Queens metro service team, and the Long Island coordination desk each support same-day and next-business-day dispatch within their respective service zones without requiring the matter to route through the central Manhattan dispatch. Out-of-state dispatch to Pfizer’s other thirty-six active foreign-qualification states is coordinated through the Undisputed Legal national dispatch network on the toll-free coordination line.

Fifth, Tier 2 verification mechanics are operationally specific. The data sources Undisputed Legal queries for each Pfizer matter include the forum state’s Secretary of State online business registry, the most recent annual-report filing on record, the most recent registered-agent change filing if any has been recorded, and CT Corporation’s own state-specific filing-entity directory. The verification record produced is a structured document containing the matter caption, the forum state, the verified registered-agent name and address as of the verification date, the entity-status designation, the filing-number reference, the most recent annual-report filing date, and the verification date itself; this record accompanies the dispatch package and is preserved as part of the chain-of-custody documentation. When verification surfaces a discrepancy — a registered-agent address that has changed since the most recent commercial-database update, an entity-status transition not yet propagated, or a filing-entity name variation not yet reconciled — the dispatching counsel is notified before the process server is dispatched, allowing counsel to update the document caption or cover letter prior to service. Multi-state coordination on matters spanning five or more Pfizer foreign-qualification states runs the verification protocol simultaneously across all forum states, producing per-state verification records that align with the same dispatch date.

What Undisputed Legal Provides — and What We Do Not

Undisputed Legal delivers documents prepared by counsel. We do not prepare pleadings, classify matters, track product-liability statutes of limitations, verify litigation captions, evaluate which Pfizer subsidiary holds NDA approval for a specific product, advise on pharmaceutical product-liability theories, or substitute for the licensed legal-counsel relationship that any litigant requires for substantive legal advice on a Pfizer matter. We deliver. Counsel decides. The scope-of-services discipline is straightforward: process service is the operational delivery function, and the substantive legal-strategy function is a separately licensed activity that belongs to counsel of record.

Specifically, Undisputed Legal does not: prepare summonses, complaints, motions, or any other pleadings; classify a matter as falling within a particular pharmaceutical product-liability theory or any other substantive legal category; track statutes of limitations or discovery-rule periods on Pfizer-related product-liability claims; verify whether a complaint caption correctly identifies the proper Pfizer subsidiary as the defendant on a specific product or NDA; evaluate which Pfizer subsidiary holds the NDA, patent, or manufacturing approval at issue on a particular matter; review or comment on the substantive merits of a pharmaceutical product-liability theory, a patent-infringement claim, an employment-discrimination claim, or any other substantive matter directed to Pfizer Inc. or its subsidiaries; provide legal advice on substituted-service election, alternative-service election, or any other procedural decision that requires substantive legal judgment.

Undisputed Legal does provide: process-server dispatch in any forum state where Pfizer Inc. maintains foreign qualification or state of organization; Tier 2 pre-dispatch verification of the current registered-agent designation through state Secretary of State records; GPS-verified affidavits of service that document the time, location, and recipient of each service attempt; same-day and next-business-day dispatch coordination through the New York metro network and the national dispatch network; multi-state coordination when a matter requires service on Pfizer Inc. in more than one foreign-qualification state simultaneously; and chain-of-custody documentation from intake through return-of-service filing.

How We Approach Service on Pfizer Inc.: A Five-Phase Operational Workflow

Undisputed Legal applies a five-phase operational workflow to every Pfizer matter, designed to produce a defensible service-of-process record from intake through return-of-service filing.

Phase 1 — Intake and caption review (without UPL classification): Counsel of record provides the matter-intake details: the docket caption, the forum state, the filing date, the documents to be served (summons and complaint, subpoena, garnishment order, restraining notice, or other process), and any matter-specific instructions on dispatch timing. Undisputed Legal’s intake review confirms the matter-intake details are operationally sufficient for dispatch — the docket caption identifies the proper-party defendant by name and state of organization, the forum state matches a Pfizer foreign-qualification jurisdiction, the documents to be served are complete and signed, and the dispatch-timing parameters fall within standard or rush-service windows. Intake review does not include legal classification of the matter; counsel of record retains responsibility for the substantive caption and the matter-merits determination.

Phase 2 — Tier 2 pre-dispatch verification: Within the seventy-two-hour window before dispatch, Undisputed Legal performs a state Secretary of State pull to confirm the current registered-agent designation, the current registered-agent address, the entity status (ACTIVE, INACTIVE, SUSPENDED, or DISSOLVED), and any name variations between the historical filings and the current docket caption. Tier 2 verification produces a contemporaneous record of the registered-agent designation as of the verification date, which is the controlling fact for any subsequent challenge to the validity of service.

Phase 3 — Document preparation: The dispatch package is assembled with the summons and complaint (or other process), a CT Corporation cover letter that identifies the matter caption and the recipient registered-agent designation, the Tier 2 verification record produced in Phase 2, and the GPS-coordinate-pre-dispatch identifier that links the document package to the specific process-server route assignment.

Phase 4 — Service execution: The process server completes service at the registered-agent address, with photo verification of the document delivery, GPS-coordinate verification of the service location at the moment of delivery, and timestamp verification of the delivery time. If the registered-agent office accepts service routinely, the photo-and-coordinate record documents the delivery; if the registered-agent office refuses service or is unavailable during business hours, the process server documents the refusal or unavailability and returns for a follow-up attempt within the next business-day window.

Phase 5 — Affidavit, return-of-service, and chain-of-custody documentation: The completed service produces an affidavit-of-service document that records the matter caption, the registered-agent name, the registered-agent address, the date and time of service, the recipient at the registered-agent office, the GPS coordinates of the service location, and the photo verification. The affidavit is filed with the originating court as the return-of-service record, and the chain-of-custody record from intake through return-of-service is preserved for any subsequent challenge to the validity of service.

Common Service-of-Process Pitfalls on Pfizer Matters — and How to Avoid Them

Counsel preparing a Pfizer matter for the first time, or coordinating service of process across the thirty-seven-state foreign-qualification architecture, may encounter several common pitfalls. Each pitfall has a specific operational consequence; recognizing the pitfall in advance allows counsel to address it before dispatch rather than after a service-of-process challenge has been raised.

Pitfall 1 — Captioning “Pfizer” without specifying the subsidiary on product-specific matters. A complaint that captions only “Pfizer Inc.” for a product-liability matter rooted in a Wyeth-legacy product, a Hospira sterile-injectables product, a Greenstone authorized-generic product, a Seagen ADC oncology product, or a pre-2003 Pharmacia product may misidentify the proper-party defendant. Service of process on the parent Pfizer Inc. for a matter that should have been captioned against the subsidiary may produce a proper-party challenge that delays the merits. Counsel should determine which subsidiary holds the NDA, patent, or manufacturing approval on the specific product at issue and caption the complaint accordingly.

Pitfall 2 — Using the legacy 235 East 42nd Street address on documents prepared after 2022. Pfizer relocated to 66 Hudson Boulevard East in 2022. Documents prepared after mid-2022 from outdated templates may continue to reference the legacy address, which can produce confusion in mailing and filing records. Service of process itself routes through C T Corporation System in the forum state and is not affected by the headquarters address, but corporate-correspondence and notice-routing on the matter should reflect the current 66 Hudson Boulevard East address.

Pitfall 3 — Naming “C T Corporation System” verbatim in Maryland or Michigan filings where the state filing uses a subsidiary brand. Maryland filings name “The Corporation Trust, Incorporated”; Michigan filings name “The Corporation Company.” Documents that address “C T Corporation System” in those states may be challenged as technically defective service. The registered-agent name on the document should match the state filing verbatim.

Pitfall 4 — Treating the 37-state architecture as static (ignoring quarterly state-level address changes). CT Corporation has restructured several state offices over the past five years, and the static routing matrix can drift over twelve to twenty-four months without active maintenance. Counsel relying on a routing matrix that was last verified more than six months ago should run Tier 2 pre-dispatch verification before dispatch rather than assuming the matrix remains current.

Pitfall 5 — Assuming Pfizer is amenable to substituted service in Delaware as state of organization without reading the specific state’s substituted-service statute. Substituted service through the Delaware Secretary of State, the Delaware long-arm statute, or the Delaware foreign-corporation service framework requires careful reading of the specific provision and the matter posture. Substituted-service election is a substantive legal decision that belongs to counsel of record; Undisputed Legal coordinates the operational dispatch but does not advise on substituted-service election.

Pitfall 6 — Treating Undisputed Legal as the decision-maker on substituted-service election or any other substantive procedural decision. The scope-of-services discipline is firm: counsel decides; Undisputed Legal delivers. Substituted-service election, alternative-service election, motion-for-leave-to-serve elections, and any other procedural decision that requires substantive legal judgment belongs to counsel of record.

Pitfall 7 — Overlooking the recent Seagen acquisition (December 2023). Counsel using older Pfizer-related templates, caption-defaults, or CRM presets that predate the December 2023 Seagen acquisition may not have updated their workflow to reflect Seagen Inc. as a separately captionable Pfizer subsidiary. ADC oncology matters, Adcetris matters, Padcev matters, Tukysa matters, and Tivdak matters that pre-existed the acquisition or arose in close proximity to the closing date should caption Seagen Inc. directly rather than only Pfizer Inc.

Pitfall 8 — Confusing Pfizer Inc. with international holding-company entities. Pfizer’s tax-structuring entities — including Pfizer Ireland Pharmaceuticals, Pfizer Manufacturing Belgium NV, and Pfizer Service Company BV (Netherlands) — are not service-of-process targets for US litigation. These entities hold IP positions, transfer-pricing arrangements, and international manufacturing rights but do not accept service for US-court matters. US litigation against Pfizer’s pharmaceutical operations routes through Pfizer Inc. (Delaware) and its US-organized subsidiaries: Wyeth LLC, Hospira, Inc., Greenstone LLC, Seagen Inc., and Pharmacia & Upjohn Company LLC. Pfizer’s SEC 10-K Item 1 and Exhibit 21 distinguish US-operating subsidiaries from international holding entities; counsel reviewing the corporate tree at matter intake should focus on the US-organized subsidiaries for service-of-process planning rather than captioning international holding entities that do not accept service for US-court matters.

Pitfall 9 — Assuming international subsidiary presence confers US service jurisdiction. Pfizer maintains substantial international subsidiary structure across Ireland, Switzerland, the Netherlands, the British Virgin Islands, and other non-US jurisdictions for tax, IP, and manufacturing purposes. These international subsidiaries do not accept service of process for US-court matters even when the underlying matter concerns products manufactured in those jurisdictions. Hague Service Convention procedures apply if a complaint specifically captions an international subsidiary as a US-court defendant, but the operational question is whether the matter requires that international defendant at all, since the US-organized subsidiaries typically hold the relevant NDAs, manufacturing approvals, and patent rights for matters litigated in US courts. Counsel should consult Pfizer’s outside counsel of record before captioning international subsidiaries; doing so unilaterally produces complicated Hague-process service that is frequently unnecessary.

Pitfall 10 — Failing to distinguish the NDA-holder from the FDA manufacturing-establishment-registration designation. Two FDA designations matter for caption discipline on pharmaceutical product-liability matters and they often name different Pfizer entities. The NDA-holder (or BLA-holder for biologics) is the entity legally responsible for the New Drug Application — typically Pfizer Inc. for original branded products, Wyeth LLC for legacy Wyeth NDAs, Greenstone LLC for authorized generics, or Pharmacia & Upjohn Company LLC, Seagen Inc., and Hospira, Inc. for their respective product portfolios. The FDA-registered manufacturing-establishment holder is the entity registered with FDA for the actual manufacturing facility producing the product — frequently Hospira, Inc. for Pfizer-network sterile injectables (Hospira’s manufacturing infrastructure produces output for multiple NDA-holders within the Pfizer tree), Pfizer Manufacturing Belgium NV for certain European-manufactured products distributed in US markets, and other entity-specific designations. Product-liability theory determines which designation controls the proper-party caption: marketing/labeling/warning-defect theories typically target the NDA-holder; manufacturing-defect theories typically target both the NDA-holder and the manufacturing-establishment-registration holder. Counsel should review FDA Establishment Registration database entries at matter intake to confirm which entity holds the manufacturing-establishment-registration for the specific product and dosage form at issue.

Service-of-Process Pricing for Pfizer Matters in NYC and Multi-State Coordination

Undisputed Legal pricing for Pfizer Inc. service in the New York metropolitan area follows the standard New York City five-borough Tier 3 rate framework. Pricing reflects the per-attempt operational cost of dispatch, GPS-verified affidavit production, and chain-of-custody documentation.

Routine service: $100-$150 per attempt. Routine service supports a first-attempt window of three to seven business days from intake, with up to three attempts included as standard before any escalation to substituted-service election by counsel of record.

Rush service: $200-$250 per attempt. Rush service compresses the first-attempt window to next-business-day from intake, and is operationally appropriate for time-sensitive matters where the seventy-two-hour Tier 2 verification window has been compressed to twenty-four to forty-eight hours.

Same-day service: $250-$300 per attempt. Same-day service supports a first-attempt window within twelve hours of intake, subject to dispatch-location and registered-agent-office-hours constraints.

Stake-out service ($325-$425 per attempt for the first hour, above the $100-$150 routine baseline rate, with additional hourly increments for extended observation) is operationally appropriate for evasive-recipient scenarios where the registered-agent office or the proper-party defendant’s office is reasonably suspected of refusing scheduled service attempts.

Skip service: $75 per attempt. Skip service is the recipient-location investigation pre-dispatch service that confirms the proper-party defendant is at the address-of-record before dispatch, which is operationally appropriate for matters where the registered-agent designation may have changed since the most recent state filing.

Pricing for matters that span multiple Pfizer foreign-qualification states is calculated on a per-state-dispatch basis with multi-state coordination overhead absorbed into the per-state rate. Counsel managing high-volume Pfizer commercial-litigation matters or multi-state pharmaceutical product-liability matters can call (800) 774-6922 for matter-specific quotes.

Frequently Asked Questions: Serving Legal Papers on Pfizer Inc.

How do I serve legal papers on Pfizer Inc.?

Service of process on Pfizer Inc. routes through C T Corporation System in the forum state where the matter is filed. Pfizer is a Delaware corporation with active foreign-qualification filings in thirty-seven states; in nearly every state where Pfizer maintains an active filing, the registered agent of record is C T Corporation System. The specific registered-agent address depends on the forum state. Counsel should run Tier 2 pre-dispatch verification through the state Secretary of State to confirm the current registered-agent designation and address before dispatch.

What is Pfizer Inc.’s registered agent?

Pfizer Inc.’s primary registered agent across nearly every active foreign-qualification state is C T Corporation System. Two states use CT Corporation’s state-specific subsidiary brands rather than the C T Corporation System name: Maryland filings name “The Corporation Trust, Incorporated,” and Michigan filings name “The Corporation Company.” These are CT Corporation’s state-specific filing entities, not separate operational entities, but service-of-process documents should address the registered agent under the precise filing-entity name on the state filing.

Where is Pfizer Inc. headquartered?

Pfizer Inc. is headquartered at 66 Hudson Boulevard East, New York, NY 10001-2189 (The Spiral) as of the 2022 corporate relocation. The legacy headquarters address at 235 East 42nd Street, New York, NY 10017 is no longer the contemporary mailing address; documents prepared after mid-2022 should reference the current address. Service of process on Pfizer Inc. routes through C T Corporation System in the forum state and is not directed to either headquarters address.

Can I serve Pfizer Inc. directly at 66 Hudson Boulevard East?

Service of process on Pfizer Inc. is not authorized at 66 Hudson Boulevard East. The corporate headquarters address is the principal executive offices of the company, but it is not the registered-agent designation for service of process. Service routes through C T Corporation System in the forum state where the matter is filed, with the specific registered-agent address depending on the forum.

Should I serve Pfizer Inc. or Wyeth LLC for a pre-2009 Wyeth product liability matter?

Wyeth LLC is the proper-party defendant for product-liability matters rooted in Wyeth-branded products, regardless of whether the alleged injury or product use occurred before or after the 2009 Pfizer acquisition. The Wyeth corporate identity continues to exist as a Delaware limited liability company, wholly owned by Pfizer Inc., and Wyeth LLC holds the legacy Wyeth-branded product NDAs. Pfizer Inc. may be named as the parent-company successor depending on the controlling state’s successor-liability framework, but the principal proper-party defendant for a Wyeth-product matter is Wyeth LLC. Counsel of record retains responsibility for the substantive proper-party determination.

How do I caption a complaint involving Pfizer’s authorized-generic version of a product?

Authorized-generic product-liability complaints should caption Greenstone LLC as the NDA-holder for the authorized-generic version of the product. Pfizer Inc. is the parent corporation, but the actual NDA-holder for an authorized-generic product is Greenstone LLC, the Delaware limited liability company that operates as Pfizer’s authorized-generics distribution subsidiary. The product-liability theory matters: the original branded version of a product is held by Pfizer Inc. or one of the historical predecessors (Wyeth LLC or Pharmacia & Upjohn Company LLC, depending on the predecessor history); the authorized-generic version is held by Greenstone LLC.

What does Undisputed Legal verify before dispatch on a Pfizer matter?

Undisputed Legal performs Tier 2 pre-dispatch verification within the seventy-two-hour window before dispatch on every Pfizer matter. Tier 2 verification confirms (a) the registered-agent designation has not changed since the most recent annual-report filing in the forum state, (b) the registered-agent address has not been updated to a new CT Corporation office location, (c) the entity status remains ACTIVE on the state Secretary of State’s records, and (d) any name variations across the historical filings are reconciled against the current docket caption. The verification produces a contemporaneous record of the registered-agent designation as of the dispatch date.

How long does service of process on Pfizer Inc. take?

Standard routine service supports a first-attempt window of three to seven business days from intake. Rush service compresses the window to next-business-day from intake. Same-day service supports a first-attempt window within twelve hours of intake, subject to dispatch-location and registered-agent-office-hours constraints. Pfizer’s C T Corporation System registered-agent network accepts service during standard business hours in the forum state; refusal of service at the registered-agent office is rare but not impossible, and Undisputed Legal coordinates follow-up attempts and substituted-service election support per counsel of record’s direction.

What is the difference between serving Pfizer Inc. in Delaware versus New York?

Delaware is Pfizer’s state of organization — the legal home of the entity itself, where matters in Delaware Court of Chancery, Delaware Superior Court, or the United States District Court for the District of Delaware route service through the Delaware Secretary of State or the Delaware-registered agent. New York is Pfizer’s largest active foreign-qualification state, with the registered-agent designation under C T Corporation System at 28 Liberty Street, New York, NY 10005, supporting service for matters filed in any New York state court (Supreme Court, Appellate Division, civil court of any county) or any New York federal district (SDNY, EDNY, NDNY, WDNY). The procedural rules differ between Delaware service and New York service, and counsel of record retains responsibility for the substantive procedural-rule determination.

How does Pfizer’s 2023 Seagen acquisition affect service-of-process planning?

The December 14, 2023 acquisition of Seagen Inc. brought a separately-organized Delaware corporation into the Pfizer subsidiary tree. ADC oncology product-liability matters, Adcetris matters, Padcev matters, Tukysa matters, and Tivdak matters require careful caption discipline that names Seagen Inc. as the legal entity holding the ADC NDAs. Counsel using older Pfizer-related templates or CRM presets that predate the December 2023 acquisition may not yet reflect Seagen Inc. as a separately captionable subsidiary. Service of process on Seagen Inc. routes through C T Corporation System in each state where Seagen maintains foreign qualification, with the registered-agent designation under the Seagen-specific state filings.

What happens if Pfizer’s registered-agent office refuses to accept service of process?

Refusal of service at the C T Corporation System registered-agent office is rare but operationally consequential when it occurs. CT Corporation’s standard practice is to accept service during normal business hours and produce a date-stamped receipt for the dispatching counsel; refusal scenarios typically arise from documents addressed under the wrong filing-entity name (e.g., addressing Maryland service to “C T Corporation System” rather than to “The Corporation Trust, Incorporated”), documents missing the required cover-letter information, or documents arriving outside the registered-agent office’s stated business-hours window. When refusal occurs, the process server documents the refusal with GPS coordinates, photographic evidence of the office, timestamp, and the specific reason cited at the office. Substituted-service election under the forum state’s substituted-service statute — leaving documents with a person of suitable age at the registered-agent address, or proceeding under the state’s long-arm statute if applicable — is a substantive legal decision that belongs to counsel of record; Undisputed Legal coordinates the operational dispatch but does not advise on substituted-service election.

Order Pfizer Inc. Service Now

Undisputed Legal coordinates Pfizer Inc. service in any forum state — federal or state, Delaware as the state of incorporation or any of the thirty-seven active foreign-qualification jurisdictions — with Tier 2 pre-dispatch verification, GPS-verified affidavits of service, and same-day or next-business-day dispatch coordination across the C T Corporation System network and the two state-specific subsidiary brand variations in Maryland and Michigan.

Service of process is the gatekeeper of litigation against any Fortune 50 pharmaceutical defendant, and operational authority over the registered-agent architecture is the difference between a defensible service record and a procedural challenge.